Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average of $4.54

Achieve Life Sciences, Inc. (NASDAQ:ACHV) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $4.54 and traded as high as $5.47. Achieve Life Sciences shares last traded at $5.41, with a volume of 108,307 shares traded.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ACHV. Lake Street Capital cut their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 5th. Jonestrading started coverage on shares of Achieve Life Sciences in a report on Wednesday, April 17th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Oppenheimer decreased their price objective on shares of Achieve Life Sciences from $18.00 to $11.00 and set an “outperform” rating for the company in a report on Monday, May 13th.

Achieve Life Sciences Price Performance

The firm has a fifty day moving average of $4.66 and a 200 day moving average of $4.55.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. On average, analysts predict that Achieve Life Sciences, Inc. will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Achieve Life Sciences

A number of large investors have recently added to or reduced their stakes in the stock. Madison Park Capital Advisors LLC bought a new position in shares of Achieve Life Sciences during the 4th quarter valued at $41,000. Virtu Financial LLC bought a new position in Achieve Life Sciences in the first quarter valued at about $59,000. Manchester Financial Inc. boosted its position in Achieve Life Sciences by 43.9% in the third quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 5,675 shares during the last quarter. Raymond James & Associates grew its stake in shares of Achieve Life Sciences by 6.3% during the 3rd quarter. Raymond James & Associates now owns 146,100 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 8,615 shares during the period. Finally, CVI Holdings LLC purchased a new stake in shares of Achieve Life Sciences during the 1st quarter valued at about $2,578,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.